Dawwas GK, Leonard CE, Garg M, et al. - By applying a database from commercial health plans in the United States between 2006 and 2017, experts designed a cross-sectional study to report trends in the use of antidiabetic medications among patients with type 2 diabetes (T2D) and heart failure (HF). Loop diuretic dose was applied as a surrogate for HF severity. Antidiabetic medication dispensing in the 90 days following HF diagnosis was measured. They observed an increase in the use of metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i), but a reduction in the use of sulfonylureas and thiazolidinediones (TZDs). The application of metformin and DPP-4i rapidly rose among patients with diabetes and HF, but a proportion of patients with moderate-severe HF continued to use TZDs over the 12-year period in the United States. Regardless of the promising cardiovascular safety profile of SGLT-2is, their use remains relatively limited.